ORIC Pharmaceuticals, Inc. (ORIC) News
Track canonical SquawkNews coverage tagged to ORIC, ORIC Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Oric Pharmaceuticals Initiated at Buy by BTIG
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:46 AM UTC
L
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target
BTIG initiated coverage on ORIC Pharmaceuticals's stock with a rating of Buy and a price target of $26.00.The price target implies an upside of 92.6% from the Sep 22 close of $13.50.Key takeaways from the analyst noteStr
EQUITY | Sep 23, 2026, 10:36 AM UTC
L
ORIC: Advancing late-stage cancer programs with strong safety profiles and robust funding through 2028
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases
NEWS | Sep 15, 2026, 03:24 PM UTC
L
ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, now in Phase III, and enozertinib for lung cancer, with a key data update expected soon. Differentiation is driven by safety a
NEWS | Sep 15, 2026, 02:56 PM UTC
L
ORIC: Late-stage cancer programs advance with strong funding, key data, and safety differentiation ahead
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with majo
EQUITY | Sep 09, 2026, 07:51 PM UTC
L
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential
Two late-stage oncology programs, rinzimetostat and enozertinib, are advancing through pivotal trials targeting high unmet needs in prostate cancer and NSCLC, respectively. Both show strong efficacy, safety, and blockbus
EQUITY | Sep 09, 2026, 12:49 PM UTC
L
ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Sep 04, 2026, 08:30 PM UTC
L
ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
EARNINGS | Aug 03, 2026, 08:07 PM UTC
L
ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (
ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (darolutamide), supported by clinical collaboration with Bayer
EQUITY | Jul 14, 2026, 08:05 PM UTC